文献速递肝病

意大利晚期MASLD患者亲属中肝病患病率及决定因素

Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-01-11

该研究前瞻性纳入4个意大利中心的98例晚期纤维化和/或肝细胞癌的MASLD先证者及160名非双胞胎一级亲属,无创筛查MASLD和晚期纤维化。亲属中MASLD患病率为56.8%,晚期纤维化为14.4%;晚期纤维化与糖尿病相关(OR 3.13),遗传风险变异未能改善纤维化风险分层。

要点

  • 晚期MASLD患者亲属中MASLD患病率为56.8%,晚期纤维化为14.4%。
  • 亲属晚期纤维化与糖尿病相关(OR 3.13 [1.16-8.45])。
  • 遗传风险变异和PRS未能改善亲属晚期纤维化的无创筛查分层。

核心结论

  • 约七分之一晚期MASLD患者亲属存在晚期纤维化,支持在该场景进行家族筛查的临床推荐。
  • 遗传风险变异在家族内贡献肝病但未显著改善纤维化风险分层。

研究设计与样本

  • 前瞻性纳入4个意大利中心的98例晚期纤维化和/或肝细胞癌的MASLD先证者及160名非双胞胎一级亲属,进行无创筛查。
  • 评估常见遗传决定因素和肝病多基因风险评分。

主要发现

  • 亲属中MASLD总体患病率为56.8%,晚期纤维化为14.4%。
  • 亲属多变量分析中MASLD与体重指数相关(OR 1.31 [1.18-1.46]),与糖尿病趋向相关(OR 5.21 [0.97-28.10]),与酒精摄入趋向相关(OR 1.32 [0.98-1.78]),与女性趋向相关(OR 0.54 [0.23-1.15])。
  • 亲属晚期纤维化与糖尿病相关(OR 3.13 [1.16-8.45]),与体重指数接近相关(OR 1.09 [1.00-1.19])。
  • PNPLA3风险变异在先证者中富集(P = .003)并过度传递至伴MASLD的亲属(P = .045)。

关键数值与推荐

  • 亲属MASLD患病率56.8%,晚期纤维化14.4%。
  • 亲属MASLD与体重指数OR 1.31(1.18-1.46),与糖尿病OR 5.21(0.97-28.10),与酒精摄入OR 1.32(0.98-1.78),与女性OR 0.54(0.23-1.15)。
  • 亲属晚期纤维化与糖尿病OR 3.13(1.16-8.45),与体重指数OR 1.09(1.00-1.19)。
  • PNPLA3风险变异在先证者中富集P = .003,过度传递至伴MASLD亲属P = .045。

临床怎么用

  • 作者结论支持临床推荐对晚期MASLD患者亲属进行家族筛查。
  • 遗传风险变异和PRS未显示有助于指导亲属晚期纤维化的无创筛查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction associated steatotic liver disease (MASLD) has a strong genetic component. The aim of this study was to examine noninvasively the prevalence of MASLD and of advanced fibrosis in relatives of patients with advanced MASLD and the risk factors for liver involvement, with a focus on the contribution of common genetic risk variants. METHODS: We prospectively enrolled 98 consecutive probands with advanced fibrosis and/or hepatocellular carcinoma caused by MASLD and 160 nontwin first-degree relatives noninvasively screened for MASLD and advanced fibrosis at 4 Italian centers. We evaluated common genetic determinants and polygenic risk scores of liver disease. RESULTS: Among relatives, prevalence of MASLD was 56.8% overall, whereas advanced fibrosis was observed in 14.4%. At multivariable analysis in relatives, MASLD was associated with body mass index (odds ratio [OR], 1.31 [1.18-1.46]) and tended to be associated with diabetes (OR, 5.21 [0.97-28.10]), alcohol intake (OR, 1.32 [0.98-1.78]), and with female sex (OR, 0.54 [0.23-1.15]), whereas advanced fibrosis was associated with diabetes (OR, 3.13 [1.16-8.45]) and nearly with body mass index (OR, 1.09 [1.00-1.19]). Despite that the PNPLA3 risk variant was enriched in probands (P = .003) and overtransmitted to relatives with MASLD (P = .045), evaluation of genetic risk variants and polygenic risk scores was not useful to guide noninvasive screening of advanced fibrosis in relatives. CONCLUSIONS: We confirmed that about 1 in 7 relatives of patients with advanced MASLD has advanced fibrosis, supporting clinical recommendations to perform family screening in this setting. Genetic risk variants contributed to liver disease within families but did not meaningfully improve fibrosis risk stratification.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Pelusi S, Ronzoni L, Rondena J, et al. Prevalence and Determinants of Liver Disease in Relatives of Italian Patients With Advanced MASLD. Clin Gastroenterol Hepatol. 2024. PMID: 38216023. doi:10.1016/j.cgh.2023.12.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。